PURE BIOSCIENCE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PURE BIOSCIENCE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.20M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $1.96M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $1.87M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $1.81M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $3.70M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $6.92M | Oct 28, 2021 |
| FY2012 | Jul 31, 2012 | $812.0K | Oct 29, 2012 |
| FY2012 | Jul 31, 2011 | $464.0K | Oct 29, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.20M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $1.96M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $1.88M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $1.85M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $3.93M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $6.92M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $1.91M | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $1.77M | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $1.83M | Oct 25, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.30M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $1.15M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $971.0K | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $1.00M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $2.08M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $4.02M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $1.18M | Oct 8, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($2.40M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($3.35M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($3.96M) | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | ($3.49M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($2.32M) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $4.0K | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | ($6.55M) | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | ($7.44M) | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | ($6.26M) | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | ($14.37M) | Oct 26, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($2.27M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($3.19M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($3.94M) | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | ($3.72M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($2.31M) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $4.0K | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | ($5.59M) | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | ($7.04M) | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | ($6.01M) | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | ($7.06M) | Oct 26, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $316.0K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $302.0K | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $297.0K | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $319.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $339.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $322.0K | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $354.0K | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $459.0K | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $779.0K | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | $927.0K | Oct 26, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $3.26M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $3.98M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $4.30M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $4.05M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $4.05M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $3.70M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $6.42M | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $5.24M | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $5.23M | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | $5.08M | Oct 26, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($2.02M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($2.53M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($3.28M) | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | ($2.42M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($1.17M) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $669.0K | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | ($2.99M) | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | ($3.89M) | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | ($4.56M) | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | ($4.99M) | Oct 26, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jul 31, 2023 | $33.0K | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $81.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $521.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $58.0K | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $7.0K | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $19.0K | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $206.0K | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | $390.0K | Oct 26, 2017 |
| FY2016 | Jul 31, 2015 | $81.0K | Oct 27, 2016 |
| FY2015 | Jul 31, 2014 | $21.0K | Oct 28, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.06M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $818.0K | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $1.83M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $4.48M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $4.30M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $6.32M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $1.93M | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $2.58M | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $3.83M | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | $7.56M | Oct 26, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $6.17M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $3.68M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $1.55M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $575.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $970.0K | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $1.51M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $742.0K | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $1.29M | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $2.54M | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | $2.54M | Oct 26, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($5.12M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($2.86M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2023 | $272.0K | Oct 29, 2025 |
| FY2024 | Jul 31, 2022 | $3.91M | Oct 29, 2024 |
| FY2023 | Jul 31, 2021 | $3.33M | Oct 30, 2023 |
| FY2022 | Jul 31, 2020 | $4.81M | Oct 28, 2022 |
| FY2021 | Jul 31, 2019 | $1.19M | Oct 28, 2021 |
| FY2020 | Jul 31, 2018 | $1.28M | Oct 8, 2020 |
| FY2019 | Jul 31, 2017 | $1.29M | Oct 30, 2019 |
| FY2018 | Jul 31, 2016 | $5.02M | Oct 25, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($138.99M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($136.60M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($133.25M) | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | ($129.28M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($125.79M) | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | ($123.47M) | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | ($123.48M) | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | ($116.92M) | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | ($109.48M) | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | ($103.22M) | Oct 26, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $334.0K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $349.0K | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $1.10M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | $3.39M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $2.39M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | $3.84M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | $398.0K | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | $851.0K | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | $1.64M | Oct 25, 2018 |
| FY2018 | Jul 31, 2016 | $5.19M | Oct 25, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jul 31, 2015 | $0 | Oct 28, 2015 |
| FY2014 | Jul 31, 2014 | $0 | Oct 28, 2014 |
| FY2013 | Jul 31, 2013 | $1.26M | Oct 24, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 0 | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | 0 | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | 0 | Oct 8, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 0 | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 0 | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | 0 | Oct 30, 2023 |
| FY2021 | Jul 31, 2021 | 0 | Oct 28, 2021 |
| FY2021 | Jul 31, 2020 | 0 | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | 0 | Oct 8, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 111.89M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | 111.86M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 111.86M | Oct 29, 2024 |
| FY2023 | Jul 31, 2022 | 111.36M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | 87.22M | Oct 28, 2022 |
| FY2021 | Jul 31, 2020 | 87.07M | Oct 28, 2021 |
| FY2020 | Jul 31, 2019 | 76.73M | Oct 8, 2020 |
| FY2019 | Jul 31, 2018 | 68.25M | Oct 30, 2019 |
| FY2018 | Jul 31, 2017 | 63.09M | Oct 25, 2018 |
| FY2017 | Jul 31, 2016 | 64.82M | Oct 26, 2017 |